Safety and patient satisfaction of abobotulinumtoxinA for aesthetic use.  A systematic review by Cohen, Joel L & Scuderi, Nicolo'
Aesthetic Surgery Journal
2017, Vol 37(S1) S32–S44
© 2017 The American Society for
Aesthetic Plastic Surgery, Inc.
This is an Open Access article 
distributed under the terms of the 
Creative Commons Attribution-
NonCommercial-NoDerivs licence 
(http://creativecommons.org/
licenses/by-nc-nd/4.0/), which 
permits non-commercial  
reproduction and distribution 
of the work, in any medium, 
provided the original work is not 
altered or transformed in any 
way, and that the work is properly 
cited. For commercial re-use, 
please contact journals. 
permissions@oup.com
DOI: 10.1093/asj/sjx010
www.aestheticsurgeryjournal.com
Supplement Article
Safety and Patient Satisfaction of 
AbobotulinumtoxinA for Aesthetic Use: 
A Systematic Review
Joel L. Cohen, MD; and Nicolo Scuderi, MD
Abstract
A systematic review of the published literature (from January 2000 to January 2016) to ascertain the safety of, and patient satisfaction with, the aesthetic 
use of abobotulinumtoxinA was conducted. In addition to the licensed indications, other special populations were considered for discussion. The potential 
impact of neutralizing antibodies and systemic toxicity were also addressed. A total of 364 papers were screened and 86 were found to be relevant to 
the population, intervention(s), and outcomes stipulated in the protocol. The safety and patient satisfaction data from these publications are discussed 
in this review.
Level of Evidence: 2
Editorial Decision date: January 5, 2017.
There is a wealth of evidence for the safety of botulinum toxin 
A (BoNT-A) in aesthetic use, which has led to its licensing in 
the temporary improvement in the appearance of moderate to 
severe glabellar lines associated with procerus and corrugator 
muscle activity in adult patients <65 years of age.1
The aim of this article was to provide an up-to-date 
review of the published safety data for BoNT-A, with a focus 
on abobotulinumtoxin-A (ABO), in the treatment of glabel-
lar lines, other areas of the face, and scar optimization, and 
to examine key safety issues such as neutralizing antibod-
ies, use in pregnancy, and systemic toxicity. In addition, the 
data supporting patient satisfaction were also addressed.
METHODS
A systematic review protocol was prepared. In January 
2016, in keeping with the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis guidelines,2 we 
searched the PubMed and Cochrane databases for litera-
ture published between January 2000 and January 2016 to 
address 6 key questions. These questions are not listed in 
order of any importance and each received equal weight in 
the review process.
Dr Cohen is an Associate Clinical Professor, Department of 
Dermatology, University of Colorado, Boulder, CO; and an Assistant 
Clinical Professor, Department of Dermatology, University of 
California Irvine, Irvine, CA. Dr Scuderi is a Full Professor of Plastic 
and Reconstructive Surgery, Department of Surgery, Sapienza 
University of Rome, Rome, Italy.
Corresponding Author:
Dr Joel L. Cohen, 5340 South Quebec Street, Suite 300, Greenwood 
Village, CO 80111, USA.  
E-mail: jcohen@aboutskinderm.com
Cohen and Scuderi S33
1. What is the clinical evidence for the safety of ABO in 
aesthetic procedures?
a. Dosage by area and concentration (based on 
dilution)
b. Injection points (identification of target posi-
tions—the neuromuscular junctions), which will 
differ based on individual patient anatomy
c. Dilution/reconstitution volume, which will differ 
by site of injection/injector
d. Technique according to region of injection
e. Repeated treatment according to region
2. What is the clinical evidence for intradermal safety of 
botulinumtoxinA in scar optimization?
a. In prevention of hypertrophic or keloid scars (re-
duction in postsurgical inflammation)
b. In postoperative healing (reduction of wound ten-
sion)
3. What is the evidence for neutralizing antibody forma-
tion as a result of ABO treatment?
a. Evidence for possible nonresponse: patients who 
have stopped responding or suddenly respond very 
weakly
4. What is the clinical experience for use of ABO treat-
ment in patients who are breastfeeding or are subse-
quently found to be pregnant?
5. What is the clinical evidence for systemic toxicity as a 
result of ABO treatment?
a. Central effects of toxins, neural plasticity
6. What is the evidence for patient satisfaction with ABO 
for aesthetic procedures?
The following keywords were used when searching the 
literature databases: abobotulinum, abobotulinumtoxin, 
abobotulinumtoxinA, adverse event, aesthetic, anaphy-
laxis, antibody, asymmetry, birth, blepharoptosis, botuli-
num, breastfeeding, bruising, conception, contraception, 
cutaneous infection, dilution, diplopia, dosage, Dysport, 
ecchymosis, ectropion, edema, entropion, fetal, fetus, flu-
like, Headache, hyperesthesia, immune, immunogenicity, 
immunological, inflammation, injection site pain, keloid, 
loss of response, maternal, neurological, neutralizing, 
neutralizing antibody, nursing, postoperative, pregnancy, 
pregnant, ptosis, repeat, repeated, safety, scar, side effect, 
strabismus, surgery, surgical, systemic, systemic toxicity, 
toxicity, urticaria, wound.
A total of 364 papers were identified and initially screened 
by Dr Vanessa Lane and 86 were found to be relevant to the 
population, intervention(s), and outcomes. These papers 
were reviewed by the authors (J.L.C. and N.S). Disagreements 
were resolved through discussion and an independent 
review of the papers was performed by Dr Andy Pickett.
RESULTS
What is the Clinical Evidence for the 
Safety of AbobotulinumtoxinA in 
Aesthetic Procedures?
Many studies have investigated the safety of BoNT-A 
as a class. In 2014, a systematic review on the safety of 
BoNT-A (ABO, incobotulinumtoxinA [INCO], and onabot-
ulinumtoxinA [ONA]) for aesthetic use was performed, 
which included data from 35 clinical studies including 
8787 individuals. Of these studies, 13 (37%) assessed 
ABO, 1 (3%) assessed INCO, and 21 (60%) assessed 
ONA.3 The overall incidence of adverse events (AEs) for 
all botulinum toxin preparations was not found to be sig-
nificantly different between experimental and placebo 
groups, and AEs were reported as being mostly mild and 
transient in nature.3 The most common AEs were bleph-
aroptosis (2.5%), brow ptosis (3.1%), and eye sensory 
disorders (3%) in the upper face, and lip asymmetries 
and imbalances in the lower face (6.9%). In a 2015 sys-
tematic review, eyelid edema was also reported in 1.4% 
of patients, with a greater risk for BoNT-A-induced eye-
lid edema reported in Asian populations than Caucasian 
populations (3.1% vs 0.7%).4
Headache, injection site pain, edema, and bruising 
have been reported and occur independently of the area 
being treated, with no statistical difference compared with 
placebo injection. This suggests that these AEs may be 
related to the injection procedure and could be avoided by 
improving injection technique.5-7
There are no reported long-term AEs related to the aes-
thetic use of ABO, INCO, or ONA.8
Studies that specifically investigated ABO have reported 
a good overall safety profile, with most AEs being minor 
and related to the trauma of injection.9,10 There are sub-
stantial safety data relating to the treatment of glabellar 
lines.11 However, safety data relating to the treatment of 
the forehead, lateral canthal lines (“crow’s feet”), and 
other anatomical areas are less well documented.10
Glabellar Lines
The safety of ABO for the treatment of glabellar lines has 
been demonstrated in 5 Phase III studies,12-15 a 24-month 
extension trial,16 and a 36-month extension trial.17 These 
clinical trials combined included over 4500 individuals who 
received up to 7 cycles of treatment. There were no reported 
serious treatment-emergent AEs (TEAEs) deemed possibly 
or probably related to treatment.17,18 Table 1 summarizes 
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the TEAEs (>1% incidence) reported in the safety popula-
tion for ABO.18
The treatment of glabellar lines with ABO was well tol-
erated, and the safety profile of ABO was comparable to 
that of placebo in terms of type, frequency, severity, and 
relatedness of TEAEs for fixed-dose and variable-dose 
treatment regimens, as well as for single and repeat-dose 
treatment.18 Each of these Phase III studies represented a 
different aspect of the safety profile of ABO.
• Rubin et al compared 311 patients who received dif-
ferent cycles of open-label treatments before entering 
the double-blinded, randomized treatment phase.15 
In this study involving open-label treatment, the inci-
dence of TEAEs did not increase over 2 to 3 treatment 
cycles (Table 1).
• Kane et al investigated the safety of variable dos-
ing in 816 individuals randomized in a 2:1 ratio to 
ABO (50, 60, 70, or 80 U) or placebo. Only slightly 
more TEAEs were reported with ABO compared with 
placebo and these differences were not statistically 
significant (31% vs 28%, respectively) (Table 1).13 In 
the cardiovascular subanalysis within this study (n 
= 79), there was no QT/QTc prolongation observed, 
where QT interval is a measure of time between the Q 
wave and the T wave in the heart's electrical cycle. It 
is widely known as QT and QTc refers to the corrected 
QT.
• Brandt et al assessed the safety of a single treat-
ment of ABO in 105 patients. TEAEs occurred in 
a similar proportion of patients in the treatment 
(49/105, 47%) and placebo (21/53, 40%) groups.12 
The most frequently occurring TEAEs were injection 
site reaction, injection site pain, nasopharyngitis, 
and headache. The majority of TEAEs were consid-
ered not related, or unlikely to be related, to study 
treatment. The incidence of eyelid ptosis in the ABO 
group was 3/105 (2.9%) compared with 0/53 (0%) in 
the placebo group, and all of the reports were mild 
and resolved without sequelae (Table 1).
• Moy et al found that up to 5 cycles of treatment with 
50 units of ABO in 1200 patients were well tolerated.14 
The results revealed no evidence of cumulative safety 
issues over the course of 13 months (Table 1).
• Cohen et al assessed the long-term cumulative safe-
ty of ABO in both fixed-unit and variable-dosing set-
tings in an extension study of patients from the 4 Phase 
III trials.16 Over 24 months, 1415 patients underwent 
open-label retreatment with ABO. Patients were retreat-
ed with 50 units or a variable dose of 50, 60, 70, or 80 
units based on sex and muscle mass. Some 932 patients 
(66%) experienced at least 1 AE. The rate of TEAEs 
was similar in both the fixed- and variable-dose groups 
and most were rated mild (70%) or moderate (20%). 
The majority (87%) of AEs were considered not relat-
ed, or unlikely to be related, to study treatment. The 
Table 1. Summary of Data Supporting the Safety of AbobotulinumtoxinA From 5 Phase III Clinical Trials Investigating its Use in the Treatment of Glabellar 
Lines: The Number of Patients With Treatment-Emergent Adverse Events With >1% Incidence Reported in the Safety Population. Reproduced With per-
mission From Aesthetic Surgery Journal, Mark Rubin et al18
TEAEs no. of patients (%) Rubin et al15 Kane et al13 Brandt et al12 Moy et al14 Cohen et al16
ABO  
n = 311
ABO  
n = 544
Placebo  
n = 272
ABO  
n = 105
Placebo  
n = 53
ABO  
n = 1200
ABO n = 1415
Fixed dose  
n = 1390
Variable dose  
n = 715a
No. of patients with any TEAEs 207 (67) 168 (31) 75 (28) 49 (47) 21 (40) 880 (73) 818 (59) 260 (36)
Nasopharyngitis 38 (12) 15 (3) 6 (2) 12 (11) 6 (11) 153 (13) 168 (12) 22 (3)
Headache 42 (14) 19 (3) 8 (3) 10 (10) 4 (8) 178 (15) 81 (6) 30 (4)
Eyelid ptosis 6 (2) 13 (2) 1 (<1) 3 (3) 0 (0) 45 (4) 30 (2) 10 (<1)
Blepharospasm 3 (1) 1 (<1) 0 (0) 1 (1) 2 (4) 15 (1) 12 (<1) 1 (<1)
Injection site pain 12 (4) 2 (<1) 4 (1) 4 (4) 2 (4) 83 (7) 50 (4) 10 (1)
Injection site bruising 16 (5) 4 (1) 0 (0) 0 (0) 1 (2) 72 (6) 30 (2) 7 (1)
Upper respiratory tract infection 6 (2) 10 (2) 4 (1) 1 (1) 0 (0) 82 (7) 67 (5) 15 (2)
Sinusitis 14 (5) 6 (1) 3 (1) 2 (2) 0 (0) 92 (8) 84 (6) 9 (1)
Influenza 10 (3) 5 (<1) 0 (0) 2 (2) 2 (4) 44 (4) 32 (2) 5 (<1)
ABO, abobotulinumtoxinA; TEAE, treatment-emergent adverse event. aPatients who received both fixed- and variable-dose treatments were counted in both groups; therefore, the total number of 
patients in the fixed- and variable-dose groups is greater than the total number in the study. 
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incidence of all TEAEs and related TEAEs remained rel-
atively constant or decreased over repeat cycles of ABO 
treatment. ABO was readministered with a minimum 
of 85 days between treatments, and then only if gla-
bellar lines returned to a moderate or severe level. The 
repeat-dose studies summarized in the article showed 
no evidence of cumulative safety issues despite the fact 
that the majority of the patients received more than 50 
units of ABO (Table 1).
• Schlessinger et al carried out a long-term extension 
trial of 36 months’ duration, which enrolled patients 
from the 4 Phase III trials, to assess the safety and effi-
cacy of repeat injections with ABO for the treatment of 
glabellar lines.17 The final results of the extension study 
in 1415 patients demonstrated that multiple cycles of 
ABO treatment over 24 months were well tolerated and 
effective for the correction of glabellar lines, with no 
evidence of cumulative safety problems over the 3 year 
study period. The AEs that patients experienced were 
typically mild to moderate in severity, and the majority 
of reported TEAEs were judged to be unlikely or not 
related to treatment.
In repeated-treatment studies of ABO, the incidence of 
TEAEs was the highest in the first cycle and decreased 
in subsequent treatment cycles.19 Approximately 91% of 
945 patients treated with ABO (median total dose/ses-
sion = 100 units) over 3 to 5 consecutive cycles expe-
rienced no AEs. The glabella was the area treated most 
frequently (93.9%), with the majority (81.5%) of patients 
also receiving treatment in other areas of the face. AEs 
decreased with repeat treatments, occurring in 39/945 
patients (4.1%) in the first treatment cycle and 11/553 
(2.0%) in the fifth treatment cycle. Ptosis was restricted to 
0.85% of patients.
A 2010 clinical overview by Rzany et al examined the 
safety of ABO for the treatment of glabellar lines in 11 
clinical studies, which involved a total of 4649 patients 
and 12,844 treatments (including the 5 pivotal studies 
already described).20 It was concluded that ABO demon-
strated good overall safety during these studies. Most of 
the TEAEs were considered unrelated to the treatment and 
the most frequent treatment-related TEAEs again included 
headache and injection site reaction. Furthermore, the 
majority of treatment-related TEAEs were mild in inten-
sity and resolved without additional treatment.20 The 
percentage of patients that reported eyelid ptosis was 
low: <3% in all single-treatment studies and <4% in all 
repeated-treatment studies. TEAEs reported by >3% of 
patients included headaches (most common), injection 
site reaction, injection site pain, nasopharyngitis, and 
upper respiratory tract infection, and generally occurred 
to a similar degree among patients receiving ABO and 
placebo.13,21,22
Other Areas of the Face (Forehead and 
Crow’s Feet)
Although ABO is commonly used in many facial areas, the 
US Food and Drug Administration (FDA) approval is spe-
cifically only for the glabella at this time. The lack of a 
large pivotal trial to support FDA approval of an indication 
other than the glabella reflects the limited published safety 
data available for the use of ABO in other facial areas.
The reported AEs in 20 patients receiving ABO 
treatment for severe frontalis lines at maximum eleva-
tion were bruising and occasional headache. Although 
the results were based on 20 treated subjects, the use 
of bilateral frontalis comparisons resulted in a statisti-
cal N = 40.23 However, injection of any BoNT-A into 
the frontalis muscles (forehead) may worsen brow pto-
sis, and injecting the lower part of the forehead should 
be avoided for this reason.8,10,24 This is particularly the 
case for patients who depend on their lateral frontalis 
to elevate their brows in an effort to avoid accentuating 
dermatochalasis.
AEs associated with the use of any of the BoNT-A formu-
lations to soften the appearance of lateral canthal rhytides 
(crow’s feet) have included bruising, diplopia, asymmetric 
smile, and lid ptosis.8
In a double-blind, placebo-controlled, dose-ranging 
study including 218 patients, Ascher et al demonstrated 
the safety of ABO at doses ranging between 15 U and 45 U 
for the treatment of lateral crow’s feet.25 The findings have 
been confirmed by more recent open-label and retrospec-
tive studies of several hundred patients.26,27
Impact of Multiple Injection Sites
The use of multiple vs single injection sites does not 
appear to impact safety outcomes for ABO treatment. 
A study comparing 1 vs 3 injection sites of ABO in the 
treatment of lateral crow’s feet in 40 patients showed no 
difference in AEs between the 2 sides.27 This finding con-
firmed the results of a previous retrospective analysis that 
found when using a total dose of ABO the same for each 
side of the face, 1 injection point had similar safety out-
comes to 3 separate injection points.26
Hexsel et al compared the safety of different doses of 
ABO administered to the entire face simultaneously.28 
Ninety patients were enrolled with at least 2 indications for 
ABO treatments on each third of the face (upper, middle, 
and lower). Patients were randomized into 3 groups, with 
a predefined total dose range of ABO (group 1, 120-165 U; 
group 2, 166-205 U; and group 3, 206-250 U). No statisti-
cally significant difference was identified between the 3 
dose groups for AEs. The incidence of AEs was low and 
events were mainly related to the injections and included 
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erythema (67%), bruising (27%), edema (13%), pain, 
pruritus and burning (2.4%), and some bleeding (4.7%). 
Only 1 patient (1.2%) reported a sensation of heaviness 
in the eyelids. This symptom was transitory and did not 
lead to eyelid ptosis. These results suggested that concom-
itant injections of ABO in various facial areas could be 
performed with no increased safety concerns.
Field of Effect
If the dose is increased, the area of effectiveness (other-
wise known as the field of effect) will increase, and by this, 
the final effect will also potentially increase.29 The field of 
effect of a BoNT-A formulation is a function of the active 
process of “spread” during injection and the subsequent 
passive process of diffusion afterward.30,31,32 The field of 
effect depends on a number of variables (including: injec-
tion volume; total dose; depth, angle, and rate of injection; 
anatomic area; desired degree of effect; and patient-spe-
cific factors)33 but today, the effect of dose on diffusion 
is considered to be the key factor influencing the field of 
effect and comparable results have been demonstrated 
between equal doses of different BoNT-A products.34
AEs related to the field of effect have been infre-
quently observed in large, randomized controlled trials 
(RCTs), as reflected by the low incidences of eyelid pto-
sis.10 When unwanted effects such as ptosis do occur, 
they can often be traced back to lack of injector expe-
rience or poor technique, which results in subsequent 
spread followed by diffusion to musculature adjacent to 
the site of injection.35
Diffusion within the tissues is slower and not depen-
dent on the injection technique,30 although volume might 
play a role in the initial spread of the toxin from the orig-
inal site of injection.36 A recent study investigating the 
field of effect in 10 patients found a larger field of effect 
(ie, mean wrinkle reduction, 794.1 vs 486.6 mm2) when a 
larger reconstitution volume (and hence injection volume) 
was used.36 Electromyography studies show that BoNT-A 
can diffuse up to 3 cm from the point of injection, mak-
ing accurate identification and injection of target muscles 
essential to achieving the desired outcome.37
What is the Clinical Evidence for 
Safety of Injection of BoNT-A in Scar 
Optimization?
BoNT-A is an ideal biochemical agent that allows near-to-
tal elimination of muscle pull on the healing facial wound. 
The goal of therapy in patients with scars has been to 
eliminate dynamic tension on the healing tissues, to both 
improve wound healing and minimize scarring for opti-
mal aesthetic results.38 Hypertrophic scarring in a range 
of areas of the body (for example, face, neck, chest, back, 
earlobes, and buttocks) can be associated with physical 
deformities, restricted range of motion, pain, and pruri-
tus.39 In these patients, BoNT-A could, in addition to relax-
ing muscle tension, affect the cell cycle distribution of 
fibroblasts derived from the hypertrophic scar.39 BoNT-A 
can also be considered as an adjunctive treatment for cuta-
neous lacerations.38
One key factor that determines the final aesthetic 
appearance of a cutaneous scar is the tension that acts 
on the wound edges during the healing phase.38 Dynamic 
tension caused by local muscle pull may be addressed 
by denervating the muscles pulling on a wound through 
chemoimmobilization.38 BoNT-A allows near-complete 
elimination of dynamic muscle tension on the healing 
wound.38
There are no published data for the use of ABO in the 
treatment of scars. The safety profile of other BoNT-A for-
mulations for scar optimization is demonstrated in several 
clinical studies as summarized below.
In a 2014 study, there were no complications reported 
when ONA was used to improve scar quality in 30 patients 
undergoing cleft lip scar revision surgery.40 Ziade et al also 
found that early injections of ONA improved the scar qual-
ity of facial wounds in 11 patients, with no safety issues 
reported.41 These safety findings confirm those of an ear-
lier study of 19 patients with persistent hypertrophic scars 
who were treated at a scar clinic using a Chinese BoNT-A 
formulation.39 In this study, BoNT-A was found to decrease 
the volume of hypertrophic scars, with injection site pain 
being the only reported AE. A 2006 study of 40 patients 
with “ugly” scars of the face found that when ONA was 
used during revision surgery to minimize tension on 
healing wound edges, 90% of patients had an improved 
outcome, and no untoward effects of BoNT-A on wound 
healing were reported.42
What is the Evidence for Neutralizing 
Antibody Formation as a Result of 
AbobotulinumtoxinA Treatment?
As with any therapeutic protein, BoNT-A may be regarded 
as foreign by the host and therefore has the potential to 
induce at least some type of immune response, particularly 
with repeated administration. ABO consists of the 150 kDa 
neurotoxin and a set of neurotoxin-associated complex-
ing proteins.43 Complexing proteins (consisting of several 
hemagglutinins and nontoxin nonhemagglutinin protein) 
may increase the risk of neutralizing antibody formation, 
which may cause secondary treatment failure, particularly 
if frequent injections are required.43,44 However, this has 
not been demonstrated clinically in any trial. Although 
the core neurotoxin is initially in the complex with neu-
rotoxin-associated proteins (as for ABO and ONA, but not 
INCO), the complex dissociates almost immediately upon 
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dilution in the vial as it encounters the neutral pH of the 
physiological solution.
In addition to the presence of complexing proteins, a 
number of other factors may impact the immunogenicity 
of BoNT-A. These include product-related factors (such as 
the manufacturing process—through causing an inactive 
toxin protein content to be formed—and the antigenic pro-
tein load) and treatment-related factors (such as the over-
all toxin dose, booster injections, and prior exposure),43 
with the most important factors believed to be the inactive 
toxin protein load per effective dose and the frequency of 
exposure.45-49 However, antibody titers required to cause 
clinical resistance to BoNT-A have not been defined and 
immune responses can differ between patients.43 The 
reported prevalence of neutralizing antibodies and treat-
ment failure is variable and may be attributed to study 
design, administered doses, indication, assay methodol-
ogy, timing of serum sample testing, and treatment his-
tory,50 and in some patients, the formation of antibodies 
may have no effect on treatment.
Not all immune responses preclude BoNT-A therapy 
from being clinically effective.43 Only antibodies that bind 
BoNT-A in a manner that neutralizes the biological activity 
sufficiently will attenuate its effect at the neuromuscular 
junction.43 Thus, the formation of antibodies may have no 
effect on treatment or may result in partial or complete 
clinical unresponsiveness to BoNT-A.48,51 Furthermore, 
patient expectation may lead to a subjective nonresponse 
to previously effective BoNT-A treatment.52
The development of neutralizing antibodies is more 
common in therapeutic indications, where doses tend to 
be much larger.43,49,53-57 Lower doses of BoNT-A prepa-
rations are used in the aesthetic field, but as treatment 
indications require repeated injections, individuals may 
be considered to be at risk for the formation of neutraliz-
ing antibodies and secondary nonresponsiveness.43,49,53-57 
Data have emerged that show that complexing proteins, 
and in particular hemagglutinins, can trigger an immune 
response against BoNT-A, however some of the data are 
questionable.43,49,53-57 The published literature in this area 
is sparse, and more data are needed to determine the true 
prevalence of resistance in the aesthetic field as well as the 
nature of the neutralizing antibodies.49
With respect to patients receiving ABO for aesthetic 
treatment, clinical studies have found no confirmed evi-
dence of neutralizing antibodies.12,14,22 Furthermore, a large 
(n = 1554) integrated review of ABO clinical trials found 
only 5 patients who had a positive screening result for neu-
tralizing antibodies using a radioimmunoprecipitation-com-
petition assay protocol.58 However, none of the positive 
findings were confirmed upon additional testing with the 
gold standard mouse protection assay, a highly specific 
bioassay that tests for neutralizing BoNT-A antibodies by 
determining the ability of sera to prevent the death of mice 
given a lethal dose of BoNT-A.58 In addition, all patients 
with a positive screening result were clinical responders to 
treatment. These findings suggest that repeated injections 
of ABO with the recommended doses did not induce the for-
mation of neutralizing antibodies under the study settings, 
and demonstrate a limited risk of secondary nonresponse.20
The development of neutralizing antibodies to ABO 
after injection for aesthetic use (either alone or with other 
BoNT-A formulations) has been reported in 7 case studies 
including 11 patients. Dressler et al reported on 2 patients in 
whom neutralizing antibodies to ABO developed after injec-
tion for aesthetic use, resulting in secondary treatment fail-
ure.56 The details of the 2 cases are summarized in Table 2.
Torres et al reported on 5 case studies in which neu-
tralizing antibodies to BoNT-A (including ABO) developed 
after injection for aesthetic use, resulting in secondary treat-
ment failure.49 The patients in this report all had a declining 
clinical response to BoNT-A over several injection sessions. 
They developed secondary treatment failure and tested pos-
itive for neutralizing antibodies using the mouse phrenic 
nerve hemidiaphragm assay, suggesting that the cause of 
the therapy failure was neutralizing antibodies to BoNT-A. 
The details of the cases are summarized in Table 3.
The absence of any substantial numbers of patients 
reported in the literature strongly indicates that the devel-
opment of antibody resistance to aesthetic use of BoNT-A 
products is highly unlikely.30
Table  2. Case Studies of Patients Developing Neutralizing Antibodies 
After ABO Injection for Aesthetic Use56
Parameter Patients receiving ABO
Case 1 Case 2
Aesthetic indication Hyperkinetic skin lines in  
the glabellar, forehead, 
and bilateral periocular 
regions
Hyperkinetic skin lines 
in the glabellar, and 
forehead regions
Previous BoNT-A  
therapy
None None
Average interinjection 
intervals, days
87 119
Minimal interinjection 
intervalsa, days
14 15
ABO single dose  
size, mean, MU
82 68
Occurrence of  
complete secondary 
treatment failure
After: 10 injection series. 
Treatment time: 
25 months
After: 5 injection series. 
Treatment time: 
16 months
Mouse HDA (mU/mL)  
(at time of complete  
secondary treatment 
failure)
7.0 >10
ABO, abobotulinumtoxinA; HDA, hemidiaphragm assay. aThe minimal interinjection intervals 
in these 2 cases were 14 and 15 days, thus constituting “booster injections” currently not 
recommended.
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What is the Clinical Experience for Use 
of AbobotulinumtoxinA Treatment in 
Patients Who Are Breastfeeding or Are 
Subsequently Found to be Pregnant?
Only a few case studies dealing with the issue of safety of 
ABO in human pregnancy have been reported. There are 
no controlled trial data and it is unlikely that such studies 
can be conducted to resolve this issue.59
Newman et al reported on clinical ONA treatment 
during pregnancy in a patient treated with BoNT-A for 
cervical dystonia.60 The patient was injected during 4 full-
term pregnancies with doses ranging from 600 U to 1200 U 
per pregnancy, without any effect on the pregnancy outcome.
In a survey of physicians who frequently used ONA, 
pregnancy outcomes were analyzed in patients who were 
pregnant at the time of BoNT-A injection.61 Twelve physi-
cians reported injecting BoNT-A in 16 pregnant women, 
mostly during the first trimester. Only 1 patient, who had 
a history of spontaneous abortions, suffered a miscarriage. 
Another woman had a therapeutic abortion. All other 
pregnancies continued to full term and there were no fetal 
malformations.
De Oliveira Monteiro reported on 2 women who were 
injected in the early first trimester but had uneventful 
pregnancies with no untoward effects on the fetus.62
What is the Clinical Evidence for 
Systemic Toxicity as a Result of 
AbobotulinumtoxinA Treatment?
Distant spread of toxin effect is the unintended extension 
of BoNT-A’s effect into areas not adjacent to the injection 
site. It is associated with higher-dose indications and 
may cause symptoms such as unexpected loss of muscle 
strength or weakness, blurred vision, and eyelid ptosis;63 
and, rarely, a life-threatening illness with symptoms con-
sistent with botulism.64
After focal injection for aesthetic use, BoNT-A should 
not be present at measurable levels in the peripheral blood, 
and studies have demonstrated this point and shown that 
administration of the recommended amounts at each treat-
ment does not lead to systemic effects.65-67 Only a minus-
cule quantity of BoNT-A is used for aesthetic purposes 
and there have been no reports of distant spread of any 
of the approved BoNT-A preparations in normal healthy 
adults.11,64 In a systematic review of 11 RCTs on the use 
of BoNT-A in facial aesthetics dating from 1977 to 2009, 
Gadhia et al concluded that the use of BoNT-A treatment 
had few or no AEs in the immediate vicinity of the injec-
tions and no systemic effects.7
There is no evidence from long-term clinical use in 
humans that BoNT-A injected into peripheral muscles, 
skin, or other tissues causes clinically detectable effects in 
the central nervous system.68,69
Despite the safety of the BoNT-A products shown in these 
studies, the potential safety outcomes of distant spread of 
toxin effect are serious.64 In 2009, the FDA required all 
manufacturers of approved and marketed BoNT-A prod-
ucts to update their labeling to include a boxed warning 
describing postmarketing safety data on distant spread of 
toxin effect.63 The warning applies equally to therapeutic 
and aesthetic uses of BoNT products. As presented in the 
Dysport US prescribing information, “the risk of symptoms 
is probably greatest in children treated for spasticity but 
symptoms can also occur in adults treated for spasticity 
and other conditions, particularly in those patients who 
Table 3. Five Case Studies of Patients Developing Neutralizing Antibodies After Botulinum Toxin Type A Injection for Aesthetic Use49
Parameter Patients receiving BoNT-A
1 2 3 4 5
Aesthetic indication Upper face Various sites  
over face
Hyperhidrosis Various sites  
over face
Upper face
BoNT-A therapy ONA No response so 
switched to ABO after 1 
treatment
ABO for 13 months 
Declining response so 
switched to ONA for 
3 months, then ABO for 
4 weeks, then INCO after 
9 months
3 treatments of ONA with 
declining duration of treatment 
effect (from 5 to 2-3 months) 
Switched to ABO (duration of 
effect 1.5 months)
ABO over period of 8 years 3 treatments of ABO 
over 2 years
Duration of treatment effect 3 months ~13 months Declining from 5 months to 
1.5 months
For first 3 years: 
6-8 months Thereafter 
<3 months
Initially 6 months, then 
2 months and then 
no response
Presence of neutralizing antibod-
ies confirmed mouse phrenic 
nerve HDA
Yes (low positive) Yes Yes Yes (high positive) Yes (high positive)
ABO, abobotulinumtoxinA; HDA, hemidiaphragm assay; INCO, incobotulinumtoxinA; ONA, onabotulinumtoxinA.
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have underlying conditions that would predispose them to 
these symptoms. In unapproved uses, including spasticity 
in children, and in approved indications, cases of spread of 
effect have been reported at doses comparable to or lower 
than the maximum recommended total dose.”
What is the Evidence for Patient 
Satisfaction With AbobotulinumtoxinA 
for Aesthetic Procedures?
Measures of Patient Satisfaction
A range of measures are used to evaluate patient satisfac-
tion and specific outcomes that are important to patients 
receiving aesthetic BoNT-A treatment.
Likert-type scales, such as the Facial Lines Treatment 
Satisfaction Questionnaire, which ranges from “very dissat-
isfied” to “very satisfied” may be used to rate patient sat-
isfaction.70 Another instrument is the Facial Line Outcome 
questionnaire, which assesses specific outcomes such as 
self-perception of age, perception of attractiveness, and the 
extent to which facial lines result in looking tired, stressed, 
or angry when that does not coincide with the way the 
patient feels.71 Patients’ attitudes on beauty and body may 
be surveyed using scales of the Freiburg Questionnaire 
on Aesthetic Dermatology and Cosmetic Surgery and the 
Freiburg Life Quality Assessment core version.35
The FACE-Q is a new patient-reported outcome instru-
ment that can be used for measuring patient perceptions 
of aesthetic facial procedures.72-74 The developers of 
the FACE-Q identified 4 domains of patient satisfaction: 
appearance appraisal, AEs, process of care, and quality 
of life. Each of these domains has a series of individual 
surveys to assess, for example, appearance appraisal of 
skin or process of care of information. Physicians trying to 
assess the patient-perceived efficacy of an aesthetic inter-
vention can handpick the qualities for their analysis met-
rics. The ability to tailor the FACE-Q content to specific 
aspects of facial anatomy, as well as to specific qualities of 
patient satisfaction, makes the FACE-Q instrument import-
ant to evidence-based medicine studies of aesthetic facial 
interventions.
Adherence, which is likely to be strongly influenced by 
patient satisfaction with outcome, may also be used as a 
measure of patient satisfaction.35 Adherence with a ther-
apeutic regimen is reflected in the choices patients make 
about continuing with a treatment plan and in their selec-
tion of specific products and procedures.35
Patient Satisfaction With Botulinum Toxin A for 
Aesthetic Procedures
A 2008 comprehensive review and meta-analyses of 23 
clinical studies including over 1500 patients found that 
patient-reported satisfaction with ABO or ONA treatment 
in aesthetic indications was consistently and significantly 
high, ranging from >65% to >90%, depending on facial 
area treated, dose, assessment, and other treatment spe-
cifics.75 Treatment also significantly improved patient 
self-perceptions and reduced perceived age relative to cur-
rent age by approximately 5 years.75
An RCT including 125 patients who received either 
ONA or placebo for glabellar lines reported high satis-
faction rates.76 The proportion of patients who were sat-
isfied with the treatment for their glabellar lines in the 
BoNT-A group remained at ≥75% for up to 120 days after 
treatment.
In another study, patients were given a questionnaire, 
which included demographic details, details of any cos-
metic treatment they had received recently and historically, 
and a copy of the Irritability-Depression-Anxiety Scale.77 
The latter provided 3 measures of mood based on 3 distin-
guishable elements (irritability, depression, and anxiety). 
The questionnaire also asked patients to provide a percent-
age value measure of their attractiveness now and prior 
to the treatment they had just received.77 BoNT-A treat-
ment to the forehead was found to result in a more posi-
tive mood in a study of 25 white female patients.77 Those 
who had received BoNT-A had a significantly more posi-
tive mood than those who had not, which was displayed 
mainly by lower anxiety and depression scores. As patients 
felt equally attractive after either treatment, an increase in 
attractiveness could not explain the difference in mood. 
This supported the study hypothesis that the paralysis of 
the corrugator (frown) muscles that made negative facial 
expressions impossible, meant that negative moods were 
harder to maintain. The lack of the negative mood feed-
back from the facial muscles was concluded to result in 
these women feeling happier.
A retrospective chart review in a private aesthetic 
surgery practice setting used retention rates to evalu-
ate patient satisfaction in patients treated with ONA.78 
Retention rates were between 70% and 76% in 60 patients 
who received ONA injections, suggesting a high level of 
patient satisfaction.78
A 2014 study by Xie et al showed that in 252 ONA 
patients treated for masseter hypertrophy (504 masse-
ter muscles), the overall patient satisfaction rate was 
95.9%.79
Dayan et al analyzed patient-reported outcomes from 
2 Phase III RCTs for ONA treatment of crow’s feet lines 
in 445 patients.80 In these trials, treated patients experi-
enced significantly greater psychological improvement and 
age-related impact, improved perception of crow’s feet line 
appearance, and treatment satisfaction compared with 
placebo.
Patient Satisfaction With AbobotulinumtoxinA for 
Aesthetic Procedures
In 2015, Molina et al reported a multicenter, prospec-
tive, noninterventional large-scale observational study in 
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525 patients in France, Germany, Spain, and the United 
Kingdom to assess the level of patient satisfaction 3 weeks 
and 4 months after the treatment of glabellar lines with 
ABO.81 Approximately half of the patients (252; 47.9%) had 
not previously received ABO in the glabellar complex, while 
266 patients (50.6%) had received another BoNT-A product 
in their glabellar region on average 12.7 months prior to 
enrollment in the present study. Two different satisfaction 
questionnaires were used, focusing on the results after 
treatment and the duration of the treatment, respectively.
A high level of satisfaction was observed at both time 
points, with 94.7% and 89.6% of patients being satisfied 
or very satisfied with the aesthetic outcome at week 3 and 
month 4, respectively (Figure 1). Patients were highly sat-
isfied with the treatment regardless of their sex or severity 
of glabellar lines at baseline, whether or not they received 
a touch-up injection, and whether or not they were naive 
to BoNT-A treatment. Of the patients who had been treated 
previously with another product, 51.2% considered the 
results obtained in the present study with ABO to be bet-
ter. Major reasons for satisfaction included the positive 
aesthetic outcome, a natural appearance, a rested look, 
and comfort of injection. The overall high level of satis-
faction with treatment corresponded to a more positive 
self-perception after the treatment. At 3 weeks after the 
treatment, 82.0% of patients said they appeared rested, 
97.5% considered the result looked natural, and 75.9% 
felt more attractive. Although 20.0% of patients felt they 
looked older than their age before any treatment was 
given, only 0.4% of patients at week 3 and 0.8% at month 
4 still thought so. Patients also felt the treatment brought 
them “harmony,” “self-esteem/confidence,” or “youth.” 
This study demonstrated that treatment of glabellar lines 
with BoNT-A resulted in a high level of patient satisfac-
tion and corresponded to a more positive self-perception 
4 months after injection.
Other studies have indicated that patient satisfaction 
with ABO for aesthetic procedures is generally high and 
correlates with the efficacy of treatment.82-84 In a retro-
spective multicountry study of repeated ABO treatments in 
the upper face involving 945 patients, patient satisfaction 
with the effect of treatment ranged from 96.0% to 98.9% 
between treatment cycles.19 A similar high level of satis-
faction was noted by physicians, ranging from 88.0% to 
94.0% between treatment cycles.
A 2011 retrospective 2-phase study of 185 patients 
treated with ABO for dynamic facial line reduction over 
an 8-month period evaluated the efficacy of and patient 
A B
C
Figure 1. Patient satisfaction regarding (A) aesthetic outcome, (B) the results compared with expectations, and  
(C) posttreatment appearance. Reproduced from Molina et al.81 Patient satisfaction after the treatment of glabellar lines with 
Botulinum toxin type A (Speywood Unit): a multi-centre European observational study, © 2014 Galderma. Journal of the 
European Academy of Dermatology and Venereology published by John Wiley & Sons, Ltd. on behalf of European Academy of 
Dermatology and Venereology.
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satisfaction with ABO injections.85 For the first phase of 
this study, ABO was administered at a concentration of 
10 U/0.1 mL saline. During the second phase, the prod-
uct was administered at a concentration of 12 U/0.1 mL 
saline. During each phase, dynamic rhytides in the follow-
ing sites were treated: crow’s feet, depressor anguli oris, 
frontalis, glabella, nasalis, mentalis, and platysmal bands. 
Combinations of treatment sites varied according to indi-
vidual patient need. Overall, the majority of patients were 
satisfied with ABO (70.9% in the first phase and 68% in 
the second phase).
The quality of life and satisfaction of patients treated 
with full-face injections of variable doses of ABO was 
investigated by Hexsel et al in a Phase IV RCT.86 Ninety 
patients, mostly women, were randomized into 3 groups, 
with predefined total dose ranges of ABO, varying from 
120 U to 250 U. The World Health Organization Quality 
of Life (WHOQOL)-BREF questionnaire and a Satisfaction 
and Self-Assessment Questionnaire (SSQ) were com-
pleted by the patients up to 6 months after treatment. 
The WHOQOL-BREF questionnaire is composed of 26 
questions that contemplate 4 different domains (physi-
cal, psychological, social relationships, and environmen-
tal).87 The SSQ included 9 questions for patients to assess 
their wrinkles, beauty, harmony, and symmetry of their 
face. The full-face approach using variable doses of ABO 
led to significant improvements in patient quality of life, 
self-assessment about their image, and level of satisfac-
tion compared with baseline. For the physical domain 
in WHOQOL-BREF a statistical difference was observed 
between baseline and at 4 weeks (P = 0.036). There was 
no difference between groups for mean grades regarding 
number of wrinkles, beauty, harmony, and symmetry. 
However, there was a significant difference in the mean 
grades for between visits (P < 0.001) for all at 4 weeks. 
Patient opinions also showed an improvement in their 
self-image up to 4 months after treatment according to the 
self-grading.
In 2016, Chang et al used FACE-Q to assess patient sat-
isfaction before and after BoNT-A treatment of glabellar 
lines.88 A total of 20 of the 57 female patients who were 
eligible for the analysis received ABO injections, and 
the remaining patients received ONA (n = 18) or INCO 
(n = 19). Patient satisfaction with the overall appear-
ance of their face increased by 18% in patients treated 
with ABO, which was not statistically significantly dif-
ferent (P = 0.33) from that of the other BoNT-A groups 
(ONA 29%, INCO 36%). Patients were more satisfied 
with how old they looked following BoNT-A injection, 
believing that they looked on average 5.6 years younger 
following any BoNT-A formulation injection. The study 
also determined that patient satisfaction with BoNT-A 
did not correlate with patient age, skin color, or degree 
of skin wrinkling, although there was an inverse trend 
for patient satisfaction, advancing age, and degree of gla-
bellar strain.
The outcomes of these studies support other data that 
demonstrate a positive patient-perceived effect of ABO 
neuromodulation on facial appearance.
DISCUSSION
This systematic review focused on key questions regarding 
the evidence for the safety of BoNT-A in aesthetic use. This 
identified 86 papers (including several clinical trials [open 
and randomized] and previous systematic literature reviews) 
that met the predefined objectives. A potential limitation of 
this review was its focus primarily on ABO, limiting its abil-
ity to draw conclusions regarding the safety of all BoNT-A 
formulations. It was also limited to PubMed and Cochrane 
databases. It would be interesting to see if further conclu-
sions could be drawn by conducting a meta-analysis of the 
safety data, providing a further and more robust analysis 
of the available studies. Overall this review provides more 
up to date information in this field, enhancing the current 
understanding and providing key information to clinicians 
when assessing the best treatment options for their patients.
CONCLUSION
The adverse event profile for ABO has been shown to be 
comparable to placebo and other formulations of BoNT-A 
across a number of indications. In aesthetic use, neither 
the incidence/impact of neutralizing antibodies nor sys-
temic toxicity has been demonstrated in clinical studies of 
ABO for aesthetic use. ABO treatment for aesthetic indica-
tions is associated with consistently and significantly high 
levels of patient satisfaction, which correlates with the effi-
cacy of treatment.
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